This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Diabetes and obesity are among the most heavily researched conditions in medicine in 2026, driven by the transformative success of GLP-1 receptor agonists. Beyond semaglutide and tirzepatide, the next generation of metabolic disease treatments — oral GLP-1s, triple receptor agonists, amylin analogs, and combination regimens — are in late-stage clinical trials. This guide covers what's being studied, who is eligible, and how patients with type 2 diabetes or obesity can participate in these high-profile research programs.
The GLP-1 Revolution and What Comes Next
Glucagon-like peptide-1 (GLP-1) receptor agonists — semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), liraglutide — have fundamentally changed the treatment of type 2 diabetes and obesity. Tirzepatide (a dual GLP-1/GIP receptor agonist) produces average weight loss of 20–22% in the SURMOUNT trials, rivaling bariatric surgery outcomes. The FLOW trial demonstrated that semaglutide reduced major kidney disease progression events by 24% in patients with type 2 diabetes and CKD — an entirely new indication.
In 2026, clinical trials are focused on the next horizon: retatrutide (GLP-1/GIP/glucagon triple agonist from Eli Lilly) produced 24.2% weight loss at 48 weeks in Phase 2, making it the most potent weight loss drug studied to date. The Phase 3 TRIUMPH program is now enrolling patients with obesity (BMI ≥30) or overweight with weight-related comorbidities across dozens of countries. Amycretin (oral GLP-1/amylin dual agonist, Novo Nordisk) showed 13.1% weight loss at 12 weeks in an early trial — extraordinary for an oral compound — and is entering Phase 3.
Oral GLP-1 Programs in Phase 3
The transition from injectable to oral GLP-1 is one of the most commercially significant developments in pharmaceutical history. Oral semaglutide (Rybelsus) is already approved for type 2 diabetes, and the OASIS Phase 3 program is evaluating higher doses (25mg, 50mg daily) for obesity. Orforglipron (Eli Lilly, small molecule GLP-1 agonist) requires no fasting or water restrictions unlike peptide oral GLP-1s and showed dose-dependent weight loss of 8.6–12.6% in Phase 2, with cardiovascular and diabetic kidney disease trials now launched in Phase 3.
Danuglipron (Pfizer) was discontinued after Phase 2 due to nausea/vomiting rates, illustrating that tolerability — not just efficacy — determines which oral GLP-1s advance. The clinical trials enrolling in 2026 for oral GLP-1 programs are generally seeking patients with BMI ≥27 with one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, sleep apnea, cardiovascular disease) or BMI ≥30 without comorbidities.
SGLT2 Inhibitors and Cardiometabolic Trials
Sodium-glucose cotransporter-2 (SGLT2) inhibitors — empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana) — have demonstrated cardiovascular and renal protective effects independent of glycemic control, reshaping how they are used. The EMPA-KIDNEY trial showed empagliflozin reduced CKD progression by 28% regardless of diabetes status. In 2026, trials are testing SGLT2 inhibitors in heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatohepatitis (MASH), and atrial fibrillation prevention.
Combination trials pairing SGLT2 inhibitors with GLP-1 agonists are examining whether the two complementary mechanisms (GLP-1 reduces caloric intake and improves beta cell function; SGLT2i promotes glucosuria and reduces cardiac/renal stress) produce additive cardiorenal benefits beyond either agent alone. The COMBINE-DKD Phase 3 trial is evaluating this combination specifically in diabetic kidney disease.
Type 1 Diabetes Trials: Beta Cell Preservation and Immune Modulation
Type 1 diabetes (T1D) research has a different focus from T2D — it centers on preserving beta cell function at diagnosis, preventing disease in at-risk individuals, and eventually restoring insulin independence. Teplizumab (Tzield, Provention Bio) — an anti-CD3 antibody that delays T1D onset by ~3 years in Stage 2 disease — achieved FDA approval in 2022, validating immune intervention in presymptomatic T1D. PROTECT Phase 3 (now fully enrolled) is testing teplizumab in recently diagnosed T1D to preserve residual C-peptide (a marker of remaining beta cell function).
Stem cell-derived beta cell therapies represent a potentially curative approach. Vertex Pharmaceuticals' VX-880 (fully differentiated stem cell-derived islets implanted without encapsulation) produced insulin independence in early patients, with the Phase 1/2 FORWARD trial ongoing. VX-264 (same cells in an immunoprotective device, eliminating the need for immunosuppression) is in Phase 1. These programs are recruiting patients with T1D who lack hypoglycemia awareness or have severe hypoglycemic episodes.
How to Find and Enroll in Diabetes and Obesity Trials
ClinicalTrials.gov filtered by "Diabetes Mellitus, Type 2" or "Obesity" under condition, with status "Recruiting," returns hundreds of active studies. Key eligibility factors to know before searching: your HbA1c (typical range 7.0–10.5% for most T2D trials), BMI (most obesity trials require ≥27 or ≥30), current medications (GLP-1 agonist or SGLT2i use may be exclusionary or required), and history of cardiovascular events or CKD (required for some cardiorenal outcome trials).
Industry-sponsored trials for novel GLP-1 compounds often run at endocrinology practices and research clinics in suburban and community settings, not just major academic centers — making them more geographically accessible than oncology or rare disease trials. The American Diabetes Association (diabetes.org) and Obesity Medicine Association maintain patient-facing information about active research programs and clinical trial participation.
Key Takeaways
- Retatrutide (triple GLP-1/GIP/glucagon agonist) achieved 24.2% weight loss in Phase 2 — the highest ever recorded for a drug — with Phase 3 TRIUMPH trials now enrolling patients with obesity or overweight with comorbidities.
- Oral GLP-1 programs (orforglipron, amycretin, high-dose oral semaglutide) are in Phase 3 targeting patients who cannot or prefer not to use injectables, with BMI ≥27 plus comorbidity as typical eligibility.
- SGLT2 inhibitor trials are expanding to HFpEF, MASH, and atrial fibrillation prevention; combination SGLT2i plus GLP-1 cardiorenal trials (COMBINE-DKD) are now enrolling in diabetic kidney disease.
- Stem cell-derived beta cell therapies (Vertex VX-880, VX-264) are in Phase 1/2 for T1D patients with severe hypoglycemia, representing a potential path to insulin independence without ongoing immunosuppression.
- Diabetes and obesity trials frequently run at community endocrinology practices, not just academic centers — making geographic access easier than many other trial types.